Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Shanghai Junshi Biosciences (688180 CH)
Watchlist
44
Analysis
Health Care
•
China
Shanghai Junshi Biosciences Co., Ltd. operates as a biopharmaceutical company. The Company develops and sells small molecule drugs, antibody drug conjugates, and other products. Shanghai Junshi Biosciences markets its products worldwide.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bearish
•
Quantitative Analysis
•
23 Oct 2022 10:25
A-H Premium Weekly (Oct 21st): Remegen, Pharmaron, Flat Glass, Shanghai Fudan, GWM, China Life
We analyzed A-H premium changes in the past week and highlight A-H premium changes for Remegen, Pharmaron, Flat Glass, Shanghai Fudan, GWM, China...
Ke Yan, CFA, FRM
Follow
280 Views
Share
bullish
•
Pylon Technologies
•
10 Oct 2022 16:12
CSI500 Index Rebalance Preview: Positioned for Outperformance
There could be 50 changes to the index in December. We estimate a one-way turnover of 13.67% at the December rebalance leading to a one-way trade...
Brian Freitas
Follow
371 Views
Share
bearish
•
Shanghai Junshi Biosciences
•
14 Jun 2022 08:30
Shanghai Junshi Bioscience Placement- Junshi Is Having a Hard Time, with Lower than Expected Returns
Junshi's Achilles heel is lack of cash and is in difficult time. PD-1/COVID-19 products can't relieve cashflow pressure.The uncertain outlook/macro...
Xinyao (Criss) Wang
Follow
297 Views
Share
bearish
•
Shanghai Junshi Biosciences
•
02 Apr 2022 19:32
Shanghai Junshi Bioscience (1877 HK): Uncertainties Prevailing Ahead of First U.S. Drug Approval
Going by the FDA’s recent action, Junshi Bioscience’s toripalimab has a chance to get rejected by the FDA. It may miss the approval timeline....
Tina Banerjee
Follow
326 Views
Share
bearish
•
Shanghai Junshi Biosciences
•
10 Jan 2022 09:05
Shanghai Junshi Bioscience (1877.HK/688180.CH) - Behind the “break Up” with AstraZeneca
The insight analyzed Junshi in terms of the potential reasons behind the termination of PD-1 commercialization partnership with AstraZeneca, the...
Xinyao (Criss) Wang
Follow
319 Views
Share
First
Previous
4
5
6
7
8
9
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.34.5
x